2000
DOI: 10.1016/s0168-8227(00)81705-2
|View full text |Cite
|
Sign up to set email alerts
|

Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0
1

Year Published

2002
2002
2011
2011

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 0 publications
0
10
0
1
Order By: Relevance
“…Clinical data reported by Cefalu et al 14 suggest that inhaled insulin is safe over 2 years of use; however, the possibility of immunologic reactions to inhaled proteins and peptides is still a major concern. Preclinical studies conducted by BioSante 15 reported minimum IgE responses to vaccine antigens formulated with CAP as an adjuvant and very little inflammation at the site of injection.…”
Section: Discussionmentioning
confidence: 99%
“…Clinical data reported by Cefalu et al 14 suggest that inhaled insulin is safe over 2 years of use; however, the possibility of immunologic reactions to inhaled proteins and peptides is still a major concern. Preclinical studies conducted by BioSante 15 reported minimum IgE responses to vaccine antigens formulated with CAP as an adjuvant and very little inflammation at the site of injection.…”
Section: Discussionmentioning
confidence: 99%
“…In a 6-month, randomised, comparative trial [77] on the patients with type 1 diabetes, severe hypoglycemia was twice as frequent with insulin Exubera as with subcutaneous regular insulin. Some studies [78,79] also reported the higher incidence of hypoglycemia with insulin Exubera than with oral hypoglycaemic agents. Another disadvantage associated with the system is the insulinantibody binding.…”
Section: Dry Powder Inhalersmentioning
confidence: 99%
“…Another disadvantage associated with the system is the insulinantibody binding. Several clinical trial studies [77][78][79] showed that during phase II and III trials, the prevalence of insulin antibodies was significantly higher in patients using insulin Exubera than in those receiving subcutaneous insulin. The levels of antibodies were higher in the patients with type 1 diabetes than those with type 2 diabetes.…”
Section: Dry Powder Inhalersmentioning
confidence: 99%
“…Zumindest bezüglich einer verstärkten Resorption des inhalierten Insulins bei Rauchern liegen Mitteilungen in Abstractform vor [33,42,57,73]. Bisherige Daten mit Beobachtungszeiträumen von bis zu 2 Jahren zeigten, dass neben der glykämischen Kontrolle auch die Lungenfunktionsparameter konstant blieben [2,9,11].…”
Section: üBersichtunclassified